Search Results 761-770 of 13241 for 🎙💯line:sammibaby💯🍓利曼集團🔶13歲可以减肥嗎?🚕澎湖县力曼傳銷🐥臺北市甩脂减肥有用🏘中坜区曼力國際🔐板桥区家用减肥器材哪個减肥好
... line therapy. The study will enroll up to 50 patients in the US and Europe. Participation eligibility. Participant eligibility includes age, gender, type and ...
About this study. This is a Decentralized Study, which means that for some, or all of the study visits, participants do not have to travel to a Mayo Clinic ...
intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema ...
The purpose of this study is the collection of Mononuclear cells (MNCs) from healthy or diseased volunteers via venipuncture and apheresis is routinely required ...
This phase 1b trial is an open-label study designed to assess the safety, tolerability, and preliminary antitumor activity of REGN5458 in combination with other ...
... line setting and are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator ...
The purpose of this study is to monitor the survival of patients who are no longer actively participating in ISIS 420915-CS2 or ISIS 420915-CS3 and were in the ...
... line of endocrine-based therapy for metastatic disease;; newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while ...
Eligibility last updated 5/13/2024. Questions regarding updates should be directed to the study team contact. Participating Mayo Clinic locations. Study ...
About this study. This research study is being done to develop better tests that can help physicians diagnose neurologic disorders earlier and with more ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.